Evidence map›Paper›PMID 33642835›Full record

Trial reportWorld journal of gastroenterology2021

Simultaneous partial splenectomy during liver transplantation for advanced cirrhosis patients combined with severe splenomegaly and hypersplenism.

Wen-Tao Jiang, Jian Yang, Yan Xie, Qing-Jun Guo, Da-Zhi Tian, Jun-Jie Li, Zhong-Yang Shen

Open access · hybridAbstract readClinical Trial
In one paragraph

Trial report in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Simultaneous CSM-TACE with CalliSpheresFrontiers in oncology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Wen-Tao JiangDepartment of Liver Transplantation, Tianjin First Center Hospital, First Clinical Institute of Tianjin Medical University, Tianjin 300192, China.
Jian YangDepartment of Liver Transplantation, Tianjin First Center Hospital, First Clinical Institute of Tianjin Medical University, Tianjin 300192, China.
Yan XieDepartment of Liver Transplantation, Tianjin First Center Hospital, First Clinical Institute of Tianjin Medical University, Tianjin 300192, China.
Qing-Jun GuoDepartment of Liver Transplantation, Tianjin First Center Hospital, First Clinical Institute of Tianjin Medical University, Tianjin 300192, China.
Da-Zhi TianDepartment of Liver Transplantation, Tianjin First Center Hospital, First Clinical Institute of Tianjin Medical University, Tianjin 300192, China.
Jun-Jie LiDepartment of Liver Transplantation, Tianjin First Center Hospital, First Clinical Institute of Tianjin Medical University, Tianjin 300192, China.
Zhong-Yang ShenDepartment of Liver Transplantation, Tianjin First Center Hospital, First Clinical Institute of Tianjin Medical University, Tianjin 300192, China. yangjian06281@126.com.
Tianjin First Center Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe most effective treatment for advanced cirrhosis and portal hypertension is liver transplantation (LT). However, splenomegaly and hypersplenism can persist even after LT in patients with massive splenomegaly.

aimTo examine the feasibility of performing partial splenectomy during LT in patients with advanced cirrhosis combined with severe splenomegaly and hypersplenism.

methodsBetween October 2015 and February 2019, 762 orthotopic LTs were performed for patients with end-stage liver diseases in Tianjin First Center Hospital. Eighty-four cases had advanced cirrhosis combined with severe splenomegaly and hypersplenism. Among these patients, 41 received partial splenectomy during LT (PSLT group), and 43 received only LT (LT group). Patient characteristics, intraoperative parameters, and postoperative outcomes were retrospectively analyzed and compared between the two groups.

resultsThe incidence of postoperative hypersplenism (2/41, 4.8%) and recurrent ascites (1/41, 2.4%) in the PSLT group was significantly lower than that in the LT group (22/43, 51.2%; 8/43, 18.6%, respectively). Seventeen patients (17/43, 39.5%) in the LT group required two-stage splenic embolization, and further splenectomy was required in 6 of them. The operation time and intraoperative blood loss in the PSLT group (8.6 ± 1.3 h; 640.8 ± 347.3 mL) were relatively increased compared with the LT group (6.8 ± 0.9 h; 349.4 ± 116.1 mL). The incidence of postoperative bleeding, pulmonary infection, thrombosis and splenic arterial steal syndrome in the PSLT group was not different to that in the LT group, respectively.

conclusionSimultaneous PSLT is an effective treatment and should be performed in patients with advanced cirrhosis combined with severe splenomegaly and hypersplenism to prevent postoperative persistent hypersplenism.

Indexed as

HypersplenismLiver TransplantationHumansLiver CirrhosisRetrospective StudiesSplenectomySplenomegalyHypersplenismLiver cirrhoticLiver transplantationMegalospleniaPartial splenectomySplenomegaly

Identifiers

PMID33642835
PMCPMC7901050
OpenAlexW3133086983

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.